|
US7045313B1
(en)
|
1982-11-30 |
2006-05-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
|
|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
|
US4751180A
(en)
|
1985-03-28 |
1988-06-14 |
Chiron Corporation |
Expression using fused genes providing for protein product
|
|
US4935233A
(en)
|
1985-12-02 |
1990-06-19 |
G. D. Searle And Company |
Covalently linked polypeptide cell modulators
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5443964A
(en)
|
1987-08-10 |
1995-08-22 |
Duke University |
Poxvirus insertion/expression vector
|
|
US6218525B1
(en)
|
1988-02-25 |
2001-04-17 |
The General Hospital Corporation |
Nucleic acid encoding CD28
|
|
US5716826A
(en)
|
1988-03-21 |
1998-02-10 |
Chiron Viagene, Inc. |
Recombinant retroviruses
|
|
US6685941B1
(en)
|
1988-11-23 |
2004-02-03 |
The Regents Of The University Of Michigan |
Methods of treating autoimmune disease via CTLA-4Ig
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5283173A
(en)
|
1990-01-24 |
1994-02-01 |
The Research Foundation Of State University Of New York |
System to detect protein-protein interactions
|
|
US6410010B1
(en)
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
|
EP0584266B1
(en)
|
1991-05-06 |
2003-09-03 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US6887471B1
(en)
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
US5844095A
(en)
|
1991-06-27 |
1998-12-01 |
Bristol-Myers Squibb Company |
CTLA4 Ig fusion proteins
|
|
DE69226871T3
(de)
|
1991-06-27 |
2009-09-24 |
Bristol-Myers Squibb Co. |
CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
|
|
US5262522A
(en)
|
1991-11-22 |
1993-11-16 |
Immunex Corporation |
Receptor for oncostatin M and leukemia inhibitory factor
|
|
ATE139900T1
(de)
|
1992-11-13 |
1996-07-15 |
Idec Pharma Corp |
Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
|
|
US5773253A
(en)
|
1993-01-22 |
1998-06-30 |
Bristol-Myers Squibb Company |
MYPPPY variants of CTL A4 and uses thereof
|
|
US6482919B2
(en)
|
1993-02-01 |
2002-11-19 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
US5457035A
(en)
|
1993-07-23 |
1995-10-10 |
Immunex Corporation |
Cytokine which is a ligand for OX40
|
|
WO1996009380A1
(en)
|
1994-09-23 |
1996-03-28 |
The University Of British Columbia |
Method of enhancing expression of mhc class i molecules bearing endogenous peptides
|
|
ATE197765T1
(de)
|
1994-10-03 |
2000-12-15 |
Us Gov Health & Human Serv |
Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
|
|
US5998205A
(en)
|
1994-11-28 |
1999-12-07 |
Genetic Therapy, Inc. |
Vectors for tissue-specific replication
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
US7153510B1
(en)
|
1995-05-04 |
2006-12-26 |
Yale University |
Recombinant vesiculoviruses and their uses
|
|
US5767071A
(en)
|
1995-06-07 |
1998-06-16 |
Ixsys Incorporated |
Sevenmer cyclic peptide inhibitors of diseases involving αv β3
|
|
US5780426A
(en)
|
1995-06-07 |
1998-07-14 |
Ixsys, Incorporated |
Fivemer cyclic peptide inhibitors of diseases involving αv β3
|
|
FR2735789B1
(fr)
|
1995-06-23 |
1997-07-25 |
Centre Nat Rech Scient |
Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
|
|
JPH11514853A
(ja)
|
1995-09-08 |
1999-12-21 |
ジエンザイム コーポレイション |
遺伝子治療のための改良されたａａｖベクター
|
|
US6750334B1
(en)
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
|
US7001765B2
(en)
|
1996-03-06 |
2006-02-21 |
Medigene Ag |
Adeno-associated virus vector for boosting immunogenicity of cells
|
|
NZ334309A
(en)
|
1996-10-25 |
2000-08-25 |
Human Genome Sciences Inc |
Neutrokine alpha protein, a member of the TNF family, and its use in treating and/or detecting immune disorders
|
|
US6294170B1
(en)
|
1997-08-08 |
2001-09-25 |
Amgen Inc. |
Composition and method for treating inflammatory diseases
|
|
US5969102A
(en)
|
1997-03-03 |
1999-10-19 |
St. Jude Children's Research Hospital |
Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
|
|
EP0979281B1
(en)
|
1997-05-02 |
2005-07-20 |
Genentech, Inc. |
A method for making multispecific antibodies having heteromultimeric and common components
|
|
US6165476A
(en)
|
1997-07-10 |
2000-12-26 |
Beth Israel Deaconess Medical Center |
Fusion proteins with an immunoglobulin hinge region linker
|
|
US5891432A
(en)
|
1997-07-29 |
1999-04-06 |
The Immune Response Corporation |
Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
|
|
JP2001517454A
(ja)
|
1997-09-19 |
2001-10-09 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
組換えアデノ随伴ウイルスの産生に有用な方法および細胞株
|
|
GB9801930D0
(en)
|
1998-01-29 |
1998-03-25 |
Univ London |
Mutant herpes simplex viruses and uses thereof
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
CA2323757C
(en)
|
1998-04-02 |
2011-08-02 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
|
US6436392B1
(en)
|
1998-05-20 |
2002-08-20 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors
|
|
US20040063094A1
(en)
|
1998-05-20 |
2004-04-01 |
Biovex Limited |
Mutant herpes simplex viruses and uses thereof
|
|
GB2337755B
(en)
|
1998-05-29 |
2003-10-29 |
Secr Defence |
Virus vaccine
|
|
WO2001060397A1
(en)
|
2000-02-16 |
2001-08-23 |
Genentech, Inc. |
Uses of agonists and antagonists to modulate activity of tnf-related molecules
|
|
CN1348463A
(zh)
|
1998-08-07 |
2002-05-08 |
华盛顿大学 |
免疫学单纯疱疹病毒抗原及其使用方法
|
|
EP1135468B1
(en)
|
1998-11-10 |
2010-01-06 |
University Of North Carolina At Chapel Hill |
Virus vectors and methods of making and administering the same
|
|
US20060067933A1
(en)
|
1999-01-07 |
2006-03-30 |
Gross Jane A |
Soluble receptor BR43x2 and methods of using
|
|
CZ303272B6
(cs)
|
1999-01-07 |
2012-07-11 |
Zymogenetics, Inc. |
Farmaceutický prostredek obsahující fúzní protein, izolovaná molekula polynukleotidu, expresní vektor, kultivovaná bunka, zpusob prípravy polypeptidu a izolovaný polypeptid
|
|
US7833529B1
(en)
|
1999-01-07 |
2010-11-16 |
Zymogenetics, Inc. |
Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
|
|
HUP0104865A3
(en)
|
1999-01-15 |
2004-07-28 |
Genentech Inc |
Polypeptide variants with altered effector function
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US8624010B1
(en)
|
1999-02-03 |
2014-01-07 |
Steven K. Yoshinaga |
Nucleic acids encoding B7RP1
|
|
GB9904582D0
(en)
|
1999-02-26 |
1999-04-21 |
Nycomed Imaging As |
Process
|
|
US6428968B1
(en)
|
1999-03-15 |
2002-08-06 |
The Trustees Of The University Of Pennsylvania |
Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
|
|
US20030022233A1
(en)
|
1999-04-30 |
2003-01-30 |
Raymond G. Goodwin |
Methods of use of the taci/taci-l interaction
|
|
US6365619B1
(en)
|
1999-07-22 |
2002-04-02 |
Novartis Ag |
Treatment of arteriosclerosis
|
|
US6596535B1
(en)
|
1999-08-09 |
2003-07-22 |
Targeted Genetics Corporation |
Metabolically activated recombinant viral vectors and methods for the preparation and use
|
|
EP1218504B1
(en)
|
1999-09-21 |
2007-07-11 |
Genetics Institute, LLC |
Gl50 molecules and uses therefor
|
|
US7241447B1
(en)
|
1999-10-07 |
2007-07-10 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors and uses thereof
|
|
US7329728B1
(en)
|
1999-10-25 |
2008-02-12 |
The Scripps Research Institute |
Ligand activated transcriptional regulator proteins
|
|
WO2001045737A2
(en)
|
1999-12-22 |
2001-06-28 |
Onyx Pharmaceuticals, Inc. |
Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth
|
|
EP1908780B1
(en)
|
2000-01-03 |
2012-08-15 |
The Trustees Of The University Of Pennsylvania |
Novel chimeric proteins and methods for using the same
|
|
JP4810042B2
(ja)
|
2000-01-21 |
2011-11-09 |
バイオヴェックス リミテッド |
ヘルペスウイルス株
|
|
EP1746106A3
(en)
|
2000-04-27 |
2007-03-14 |
Biogen Idec MA Inc. |
Use of TACI as an anti-tumor agent
|
|
US20040013674A1
(en)
|
2001-04-27 |
2004-01-22 |
Christine Ambrose |
Taci as an anti-tumor agent
|
|
NZ521629A
(en)
|
2000-04-27 |
2004-05-28 |
Biogen Inc |
TACI as an anti-tumor agent
|
|
AU2001263114A1
(en)
|
2000-05-12 |
2001-11-26 |
Amgen Inc |
Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
|
|
TWI314933B
(en)
*
|
2000-05-26 |
2009-09-21 |
Bristol Myers Squibb Compan |
Soluble ctla4 mutant molecules and uses thereof
|
|
US7094874B2
(en)
|
2000-05-26 |
2006-08-22 |
Bristol-Myers Squibb Co. |
Soluble CTLA4 mutant molecules
|
|
EP1294949A4
(en)
|
2000-06-15 |
2004-08-25 |
Human Genome Sciences Inc |
HUMAN TUMORNESCROSE FACTOR DELTA AND EPSILON
|
|
US7879328B2
(en)
|
2000-06-16 |
2011-02-01 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to B lymphocyte stimulator
|
|
AU2001268427B2
(en)
|
2000-06-16 |
2007-03-29 |
Glaxosmithkline Intellectual Property Limited |
Antibodies that immunospecifically bind to blys
|
|
US7220840B2
(en)
|
2000-06-16 |
2007-05-22 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to B lymphocyte stimulator protein
|
|
AU2001272978A1
(en)
|
2000-06-23 |
2002-01-08 |
Maxygen, Inc. |
Novel co-stimulatory molecules
|
|
US7183376B2
(en)
|
2000-06-23 |
2007-02-27 |
Maxygen, Inc. |
Variant B7 co-stimulatory molecules
|
|
CA2630062C
(en)
|
2000-07-03 |
2014-10-14 |
Bristol-Myers Squibb Company |
Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule
|
|
US20040022787A1
(en)
|
2000-07-03 |
2004-02-05 |
Robert Cohen |
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
|
|
US7011972B2
(en)
|
2000-07-18 |
2006-03-14 |
The Scripps Research Institute |
Fusion polypeptide comprising two ligand binding domains
|
|
AU2002238052A1
(en)
|
2001-02-20 |
2002-09-04 |
Zymogenetics, Inc. |
Antibodies that bind both bcma and taci
|
|
US6653103B2
(en)
|
2001-03-30 |
2003-11-25 |
Wisconsin Alumni Research Foundation |
Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides
|
|
ATE390931T1
(de)
|
2001-05-23 |
2008-04-15 |
Bristol Myers Squibb Co |
Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
|
|
PL403488A1
(pl)
|
2001-05-24 |
2013-07-08 |
Zymogenetics, Inc. |
Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina
|
|
US7189820B2
(en)
|
2001-05-24 |
2007-03-13 |
Human Genome Sciences, Inc. |
Antibodies against tumor necrosis factor delta (APRIL)
|
|
JP4572276B2
(ja)
|
2001-06-29 |
2010-11-04 |
ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ |
Ｔ細胞調節遺伝子およびその使用方法
|
|
KR100453877B1
(ko)
|
2001-07-26 |
2004-10-20 |
메덱스젠 주식회사 |
연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
|
|
KR20040019105A
(ko)
|
2001-08-03 |
2004-03-04 |
제넨테크, 인크. |
ＴＡＣＩｓ 및 ＢＲ3 폴리펩티드 및 이의 용도
|
|
US6871421B2
(en)
|
2001-09-21 |
2005-03-29 |
Daniel R. Potter |
Footwear with bladder type stabilizer
|
|
CN1304559C
(zh)
|
2001-10-09 |
2007-03-14 |
杭州康科生物技术有限公司 |
表达热休克蛋白的溶瘤微生物及其应用
|
|
EP1456652A4
(en)
|
2001-11-13 |
2005-11-02 |
Dana Farber Cancer Inst Inc |
IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
|
|
WO2003055979A2
(en)
|
2001-11-16 |
2003-07-10 |
Human Genome Sciences, Inc. |
ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
|
|
DE60235041D1
(de)
|
2001-11-30 |
2010-02-25 |
Us Gov Health & Human Serv |
Und ihre verwendung
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
BR0313033A
(pt)
|
2002-07-25 |
2007-07-10 |
Genentech Inc |
anticorpos, anticorpos monoclonais, linhagens de células de hibridoma, anticorpos receptores de anti-taci isolados, anticorpos anti -taci, métodos de modulação da atividade biológica
|
|
CA2499837C
(en)
|
2002-10-03 |
2013-12-03 |
Wyeth Holdings Corporation |
Human papillomavirus polypeptides and immunogenic compositions
|
|
US20050009149A1
(en)
|
2002-10-11 |
2005-01-13 |
West James W. |
Production of homotrimeric fusion proteins
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
HUE035898T2
(en)
|
2002-12-16 |
2018-05-28 |
Genentech Inc |
Immunoglobulin variants and their applications
|
|
TWI328614B
(en)
|
2002-12-23 |
2010-08-11 |
Bristol Myers Squibb Co |
Product quality enhancement in mammalian cell culture processes for protein production
|
|
WO2004060911A2
(en)
|
2002-12-30 |
2004-07-22 |
Amgen Inc. |
Combination therapy with co-stimulatory factors
|
|
US7563869B2
(en)
|
2003-01-23 |
2009-07-21 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human PD-1
|
|
ES2537738T3
(es)
|
2003-06-05 |
2015-06-11 |
Genentech, Inc. |
Terapia de combinación para trastornos de células B
|
|
US20050163775A1
(en)
|
2003-06-05 |
2005-07-28 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
|
MXPA05013879A
(es)
|
2003-06-18 |
2006-06-27 |
Genelux Corp |
Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos.
|
|
NZ545314A
(en)
|
2003-08-04 |
2009-03-31 |
Bristol Myers Squibb Co |
Methods for treating cardiovascular disease using a soluble CTLA4 molecule
|
|
WO2005042009A1
(en)
|
2003-10-20 |
2005-05-12 |
Biogen Idec Ma Inc. |
Therapeutic regimens for baff antagonists
|
|
PT1718677E
(pt)
|
2003-12-19 |
2012-07-18 |
Genentech Inc |
Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
|
|
WO2005100402A1
(en)
|
2004-04-13 |
2005-10-27 |
F.Hoffmann-La Roche Ag |
Anti-p-selectin antibodies
|
|
EP3342782B1
(en)
|
2004-07-15 |
2022-08-17 |
Xencor, Inc. |
Optimized fc variants
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
JP4958555B2
(ja)
|
2004-09-22 |
2012-06-20 |
協和発酵キリン株式会社 |
安定化されたヒトＩｇＧ４抗体
|
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
|
EP1812472A1
(en)
|
2004-11-04 |
2007-08-01 |
Genentech, Inc. |
Polypeptides that bind baff and/or april
|
|
EP1819823A2
(en)
|
2004-12-01 |
2007-08-22 |
Bayer Schering Pharma Aktiengesellschaft |
Generation of replication competent viruses for therapeutic use
|
|
BRPI0518994A2
(pt)
|
2004-12-31 |
2008-12-02 |
Biogen Idec Inc |
anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
|
|
KR101374454B1
(ko)
|
2005-03-31 |
2014-03-17 |
추가이 세이야쿠 가부시키가이샤 |
회합제어에 의한 폴리펩티드 제조방법
|
|
PL1868635T3
(pl)
|
2005-04-06 |
2017-10-31 |
Bristol Myers Squibb Co |
Metody leczenia zaburzeń immunologicznych związanych z transplantacją narządów rozpuszczalnymi zmutowanymi cząsteczkami CTLA4
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
US8808696B2
(en)
|
2005-08-09 |
2014-08-19 |
Ares Trading S.A. |
Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
|
|
KR20080056714A
(ko)
|
2005-08-09 |
2008-06-23 |
지모제넥틱스, 인코포레이티드 |
ＴＡＣＩ―Ｉｇ 융합 분자를 사용하여 Ｂ―세포 악성종양을치료하는 방법
|
|
US20090226440A1
(en)
|
2005-08-12 |
2009-09-10 |
Shane Grey |
Prophylactic and/or Therapeutic Method for Treatment of Autoimmune Disease
|
|
JP2007103345A
(ja)
|
2005-09-07 |
2007-04-19 |
Toyota Motor Corp |
チューブ状固体高分子型燃料電池、及びチューブ状固体高分子型燃料電池の製造方法
|
|
WO2007030803A2
(en)
|
2005-09-09 |
2007-03-15 |
Zymogenetics, Inc. |
Method for preparing trimeric proteins
|
|
KR20080074120A
(ko)
|
2005-10-13 |
2008-08-12 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
|
|
US9168286B2
(en)
|
2005-10-13 |
2015-10-27 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
|
GB0522476D0
(en)
|
2005-11-03 |
2005-12-14 |
Biovex Ltd |
Oncolytic herpes virus vectors
|
|
PT2253644E
(pt)
|
2005-12-20 |
2014-01-23 |
Bristol Myers Squibb Co |
Composições e métodos para a produção de uma composição
|
|
WO2007134326A2
(en)
|
2006-05-15 |
2007-11-22 |
Ares Trading S.A. |
Methods for treating autoimmune diseases using a taci-ig fusion molecule
|
|
WO2008011636A2
(en)
|
2006-07-21 |
2008-01-24 |
California Institute Of Technology |
Targeted gene delivery for dendritic cell vaccination
|
|
KR20090058532A
(ko)
|
2006-08-28 |
2009-06-09 |
아레스 트레이딩 에스.에이. |
Ｆｃ융합 단백질을 정제하는 방법
|
|
JP2010501623A
(ja)
|
2006-08-28 |
2010-01-21 |
アレス トレーディング ソシエテ アノニム |
Ｆｃ含有タンパク質の精製法
|
|
JP2010501622A
(ja)
|
2006-08-28 |
2010-01-21 |
アレス トレーディング ソシエテ アノニム |
Ｆｃ−融合タンパク質の精製法
|
|
EP2415783B1
(en)
|
2006-10-16 |
2016-12-14 |
Genelux Corporation |
Modified vaccinia virus strains for use in a diagnostic and therapeutic method
|
|
GB0620934D0
(en)
*
|
2006-10-20 |
2006-11-29 |
Cambridge Antibody Tech |
Protein variants
|
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
|
EP2121931B1
(en)
|
2007-01-26 |
2011-05-11 |
Merck Serono S.A. |
Purification of fc-tact fusion proteins using the oilbody technology
|
|
CA2681728C
(en)
|
2007-03-27 |
2015-12-22 |
Zymogenetics, Inc. |
Combination of blys and/or april inhibition and immunnosuppressants for treatment of autoimmune disease
|
|
US8389282B2
(en)
|
2007-03-30 |
2013-03-05 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
|
|
ES2681195T3
(es)
|
2007-06-13 |
2018-09-12 |
Zymogenetics, Inc |
Utilización de la proteína de fusión TACI-Ig, tal como atacicept, para la fabricación de un medicamento para el tratamiento de lupus eritematoso
|
|
WO2008156655A2
(en)
|
2007-06-15 |
2008-12-24 |
Genelux Corporation |
Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
|
|
CN101323643B
(zh)
|
2007-06-15 |
2010-12-01 |
烟台荣昌生物工程有限公司 |
优化的TACI-Fc融合蛋白
|
|
US8563521B2
(en)
|
2007-06-21 |
2013-10-22 |
Technische Universitat Munchen |
Biological active proteins having increased in vivo and/or in vitro stability
|
|
CN101784564B
(zh)
|
2007-07-13 |
2014-07-02 |
约翰霍普金斯大学 |
B7-dc变体
|
|
JP2010533718A
(ja)
|
2007-07-18 |
2010-10-28 |
ジェネラックス・コーポレイション |
腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用
|
|
DK2233149T3
(en)
|
2007-10-16 |
2016-05-17 |
Zymogenetics Inc |
COMBINATION OF TRANSMEMBRANAKTIVATOR AND CALCIUM MODULATOR AND cyclophilin-LIGAND INTERAKTOR (TACI) AND ANTI-CD20 MEANS FOR TREATMENT OF AUTO-IMMUNE DISEASE
|
|
EP2203465A1
(en)
|
2007-10-22 |
2010-07-07 |
Merck Serono S.A. |
Method for purifying an fc-containing protein
|
|
WO2009054996A2
(en)
|
2007-10-25 |
2009-04-30 |
Genelux Corporation |
Systems and methods for viral therapy
|
|
CA2703263C
(en)
|
2007-11-01 |
2014-03-18 |
Perseid Therapeutics Llc |
Immunosuppressive polypeptides and nucleic acids
|
|
US20100239580A1
(en)
|
2007-11-12 |
2010-09-23 |
Area Trading S.A. |
Taci-immunoglobulin fusion proteins for treatment of optic neuritis
|
|
CA2705435A1
(en)
|
2007-11-12 |
2009-05-22 |
Ares Trading S.A. |
Taci-immunoglobulin fusion proteins for treatment of relapsing multiple sclerosis
|
|
AU2008322930B2
(en)
|
2007-11-12 |
2014-05-15 |
Ares Trading S.A. |
Formulations for TACI-immunoglobulin fusion proteins
|
|
AU2008329518A1
(en)
|
2007-11-27 |
2009-06-04 |
Viventia Biotechnologies Inc. |
Antibodies against a cancer-associated epitope of variant NFKBIB and uses thereof
|
|
LT2222861T
(lt)
|
2007-12-11 |
2018-03-26 |
The University Of North Carolina At Chapel Hill |
Retrovirusiniai vektoriai modifikuoti polipurino atkarpa
|
|
ES2951646T3
(es)
|
2008-02-21 |
2023-10-24 |
Burnham Institute For Medical Res |
Métodos y composiciones relacionados con péptidos y proteínas con elementos C-terminales
|
|
WO2009126688A2
(en)
|
2008-04-09 |
2009-10-15 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
|
CA2720682A1
(en)
|
2008-04-25 |
2009-10-29 |
Zymogenetics, Inc. |
Levels of bcma protein expression on b cells and use in diagnostic methods
|
|
US8003335B2
(en)
|
2008-04-30 |
2011-08-23 |
Universite Paris-SUD11 |
Levels of APRIL in serum and use in diagnostic methods
|
|
CA2720651C
(en)
|
2008-05-01 |
2020-03-10 |
Zymogenetics, Inc. |
Levels of blys/april heterotrimers in serum and use in diagnostic methods
|
|
US7915222B2
(en)
|
2008-05-05 |
2011-03-29 |
Bristol-Myers Squibb Company |
Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
|
|
WO2009139921A2
(en)
|
2008-05-16 |
2009-11-19 |
Genelux Corporation |
Microorganisms for preventing and treating neoplasms accompanying cellular therapy
|
|
EP2310409A2
(en)
|
2008-06-17 |
2011-04-20 |
Apogenix GmbH |
Multimeric tnf receptors
|
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
WO2010059253A2
(en)
|
2008-11-24 |
2010-05-27 |
Massachusets Institute Of Technology |
Methods and compositions for localized agent delivery
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
US8629119B2
(en)
|
2009-02-04 |
2014-01-14 |
The Board Of Regents, The University Of Texas System |
Dual targeting of MIR-208 and MIR-499 in the treatment of cardiac disorders
|
|
EP2396035A4
(en)
|
2009-02-12 |
2012-09-12 |
Human Genome Sciences Inc |
USE OF ANTAGONISTS OF THE B-LYMPHOCYTE STIMULATOR PROTEIN TO PROMOTE TRANSPLANT TOLERANCE
|
|
WO2010136480A1
(en)
|
2009-05-28 |
2010-12-02 |
Glaxo Group Limited |
Antigen-binding proteins
|
|
US20150359909A1
(en)
|
2009-07-16 |
2015-12-17 |
University College Cork-National University Of Ireland, Cork |
Orally administered bacteria as vehicles for systemic delivery of agents
|
|
EP2283810A1
(en)
|
2009-07-16 |
2011-02-16 |
University College Cork-National University of Ireland, Cork |
Orally administered bacteria as vehicles for systemic delivery of agents
|
|
EP2464661B1
(en)
|
2009-08-13 |
2018-01-17 |
The Johns Hopkins University |
Methods of modulating immune function with anti-b7-h7cr antibodies
|
|
WO2011041613A2
(en)
|
2009-09-30 |
2011-04-07 |
Memorial Sloan-Kettering Cancer Center |
Combination immunotherapy for the treatment of cancer
|
|
US9540426B2
(en)
|
2009-10-06 |
2017-01-10 |
Bristol-Myers Squibb Company |
Mammalian cell culture processes for protein production
|
|
CA2791975C
(en)
|
2010-02-04 |
2021-02-09 |
The Trustees Of The University Of Pennsylvania |
Icos critically regulates the expansion and function of inflammatory human th17 cells
|
|
EP3053932B1
(en)
|
2010-02-19 |
2020-07-22 |
Xencor, Inc. |
Novel ctla4-ig immunoadhesins
|
|
WO2011109280A1
(en)
|
2010-03-05 |
2011-09-09 |
Lerner Research Institute |
Methods and compositions to treat immune-mediated disorders
|
|
US8993524B2
(en)
|
2010-03-05 |
2015-03-31 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
WO2011113019A2
(en)
*
|
2010-03-12 |
2011-09-15 |
Abbott Biotherapeutics Corp. |
Ctla4 proteins and their uses
|
|
WO2011133886A2
(en)
|
2010-04-23 |
2011-10-27 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
|
CN101851278B
(zh)
|
2010-05-26 |
2013-03-13 |
石药集团中奇制药技术（石家庄）有限公司 |
B细胞激活因子拮抗剂及其制备方法与用途
|
|
WO2011160086A2
(en)
|
2010-06-18 |
2011-12-22 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to treat asthma and other allergic and inflammatory conditions of the respiratory system
|
|
KR20130118315A
(ko)
|
2010-09-10 |
2013-10-29 |
타이제닉스, 에스.에이.유. |
줄기세포 배양 배지 및 방법
|
|
CN103261217B
(zh)
|
2010-11-11 |
2017-04-26 |
港大科桥有限公司 |
可溶性 pd‑1变体、融合构建体及其用途
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
JP2014509841A
(ja)
|
2011-01-18 |
2014-04-24 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
癌を治療するための組成物および方法
|
|
CN102085368B
(zh)
|
2011-01-19 |
2013-06-12 |
烟台荣昌生物工程有限公司 |
优化的TACI-Fc融合蛋白用于制备治疗系统性红斑狼疮药物的应用
|
|
WO2012125850A1
(en)
|
2011-03-16 |
2012-09-20 |
Amgen Inc. |
Fc variants
|
|
NZ616304A
(en)
|
2011-04-08 |
2016-01-29 |
Immune Design Corp |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
|
EP3415528B1
(en)
|
2011-04-13 |
2021-05-26 |
Bristol-Myers Squibb Company |
Fc fusion proteins comprising novel linkers or arrangements
|
|
WO2012149364A1
(en)
|
2011-04-28 |
2012-11-01 |
Diamond Don J |
Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy
|
|
US8609625B2
(en)
|
2011-06-24 |
2013-12-17 |
Taipei Veterans General Hospital |
Method for enhancing immune response in the treatment of infectious and malignant diseases
|
|
RU2657440C2
(ru)
|
2011-06-30 |
2018-06-13 |
Джензим Корпорейшн |
Ингибиторы т-клеточной активации
|
|
KR20140060541A
(ko)
|
2011-09-16 |
2014-05-20 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
암을 치료하기 위한 rna 조작된 t 세포
|
|
WO2013041029A1
(en)
*
|
2011-09-23 |
2013-03-28 |
Igenimed Pharmaceuticals Inc. |
Novel soluble ctla4 variants
|
|
US8956619B2
(en)
|
2011-10-25 |
2015-02-17 |
University Of Maryland, Baltimore County |
Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
|
|
TWI476001B
(zh)
|
2011-12-26 |
2015-03-11 |
Ind Tech Res Inst |
三倍體Ｆｃ融合蛋白及其用途
|
|
CN104302408B
(zh)
|
2012-02-27 |
2016-12-14 |
阿穆尼克斯运营公司 |
Xten缀合组合物和制造其的方法
|
|
CN102585016B
(zh)
|
2012-03-06 |
2014-06-04 |
江苏健德生物药业有限公司 |
一种可同时抑制t、b淋巴细胞功能的免疫融合蛋白、其制备方法及其应用
|
|
US9758566B2
(en)
|
2012-03-29 |
2017-09-12 |
The General Hospital Corporation |
Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
|
|
AU2013237900B2
(en)
|
2012-03-30 |
2017-07-27 |
Immune Design Corp. |
Lentiviral vector particles having improved transduction efficiency for cells expressing DC- SIGN
|
|
MX355234B
(es)
*
|
2012-05-11 |
2018-04-11 |
Medimmune Ltd |
Variantes de antigeno 4 del linfocito t citotoxico (ctla-4).
|
|
US20130319861A1
(en)
|
2012-05-30 |
2013-12-05 |
Berkeley Lights, Inc. |
Outputting A Droplet Of Liquid Medium From A Device For Processing Micro-Objects In The Medium
|
|
MX2014014951A
(es)
|
2012-06-06 |
2015-03-13 |
Oncomed Pharm Inc |
Agentes aglutinantes que modulan la trayectoria hippo y sus usos.
|
|
AU2013284460A1
(en)
|
2012-06-27 |
2015-01-29 |
Dmnomore |
CTLA4 fusion proteins for the treatment of diabetes
|
|
JP5857896B2
(ja)
|
2012-07-06 |
2016-02-10 |
東京エレクトロン株式会社 |
成膜装置の運転方法及び成膜装置
|
|
US10117896B2
(en)
|
2012-10-05 |
2018-11-06 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
WO2014089169A2
(en)
|
2012-12-04 |
2014-06-12 |
Oncomed Pharmaceuticals, Inc. |
Immunotherapy with binding agents
|
|
CN103232542B
(zh)
|
2013-02-01 |
2015-05-13 |
殷勇 |
一种双靶标嵌合蛋白
|
|
US10065987B2
(en)
|
2013-02-12 |
2018-09-04 |
Bristol-Myers Squibb Company |
High pH protein refolding methods
|
|
EP2956468B1
(en)
|
2013-02-12 |
2020-06-10 |
Bristol-Myers Squibb Company |
Tangential flow filtration based protein refolding methods
|
|
US9944689B2
(en)
|
2013-03-07 |
2018-04-17 |
The General Hospital Corporation |
Human CTLA4 mutants and use thereof
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
JP2016515120A
(ja)
|
2013-03-15 |
2016-05-26 |
バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． |
抗アルファｖベータ５抗体を用いた急性腎損傷の治療及び予防
|
|
WO2014198002A1
(en)
|
2013-06-14 |
2014-12-18 |
Ottawa Hospital Research Institute |
A bacterium producing an interferon binding protein and uses thereof
|
|
GB201311475D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Polypeptides
|
|
US20160271218A1
(en)
|
2013-06-27 |
2016-09-22 |
Mor Research Applications Ltd. |
Soluble ctla-4 molecules and derivatives thereof for treatment of minimal change disease
|
|
TWI888366B
(zh)
|
2013-07-16 |
2025-07-01 |
美商建南德克公司 |
利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法
|
|
CN110903398B
(zh)
|
2014-01-15 |
2023-08-15 |
豪夫迈·罗氏有限公司 |
具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
|
|
CN105916883B
(zh)
|
2014-01-28 |
2019-12-03 |
北京韩美药品有限公司 |
双功能融合蛋白及其制备方法和用途
|
|
EP3105333B1
(en)
|
2014-02-10 |
2020-04-08 |
Emory University |
Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
|
|
WO2015164595A1
(en)
|
2014-04-25 |
2015-10-29 |
Bristol-Myers Squibb Company |
Use of ctla4 compound for achieving drug-free remission in subjects with early ra
|
|
US10562954B2
(en)
|
2014-05-12 |
2020-02-18 |
Shanghai Kanda Biotechnology Co., Ltd. |
Fusion protein inhibiting TACI-BAFF complex formation and preparation method therefor and use thereof
|
|
KR20150135148A
(ko)
*
|
2014-05-23 |
2015-12-02 |
주식회사 제넥신 |
Pd-l1 융합 단백질 및 이의 용도
|
|
ES2715018T3
(es)
|
2014-05-30 |
2019-05-31 |
Ventana Med Syst Inc |
Ensayo múltiple para puntuar mejor los tejidos tumorales teñidos para PD-L1
|
|
MX2017000630A
(es)
|
2014-07-15 |
2017-04-27 |
Immune Design Corp |
Regimenes de sensibilización-refuerzo con un adyuvante de agonista tlr4 y un vector lentiviral.
|
|
DK3552615T3
(da)
|
2014-07-16 |
2022-02-14 |
Transgene |
Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
|
|
MX2016017288A
(es)
|
2014-07-16 |
2017-06-27 |
Genentech Inc |
Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer.
|
|
EP3177640B1
(en)
|
2014-08-08 |
2020-05-06 |
The Board of Trustees of the Leland Stanford Junior University |
High affinity pd-1 agents and methods of use
|
|
WO2016023001A1
(en)
|
2014-08-08 |
2016-02-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Multispecific high affinity pd-1 agents and methods of use
|
|
CA2959105C
(en)
|
2014-09-03 |
2023-10-17 |
Bavarian Nordic A/S |
Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
|
|
US20160145344A1
(en)
|
2014-10-20 |
2016-05-26 |
University Of Southern California |
Murine and human innate lymphoid cells and lung inflammation
|
|
CA2966988A1
(en)
|
2014-11-06 |
2016-05-12 |
Children's Research Institute, Children's National Medical Center |
Immunotherapeutics for cancer and autoimmune diseases
|
|
EP3020816A1
(en)
|
2014-11-11 |
2016-05-18 |
University College Cork |
Bacterial mediated gene therapy
|
|
NL2014108B1
(en)
|
2015-01-09 |
2016-09-30 |
Aduro Biotech Holdings Europe B V |
Altered april binding antibodies.
|
|
WO2016118577A1
(en)
|
2015-01-22 |
2016-07-28 |
Medimmune, Llc |
Thymosin-beta-four fusion proteins
|
|
AU2016240411A1
(en)
|
2015-04-02 |
2017-10-12 |
Cancure Limited |
Agents and compositions for eliciting an immune response
|
|
SMT202100467T1
(it)
|
2015-04-17 |
2021-09-14 |
Alpine Immune Sciences Inc |
Proteine immunomodulatorie con affinità regolabili
|
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Ｔｉｇｉｔ結合劑和彼之用途
|
|
TWI833684B
(zh)
|
2015-06-25 |
2024-03-01 |
美商生物細胞基因治療有限公司 |
嵌合抗原受體（ｃａｒ）、組合物及其使用方法
|
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
PE20231958A1
(es)
|
2015-07-30 |
2023-12-06 |
Macrogenics Inc |
Moleculas de union a pd-1 y metodos de uso de las mismas
|
|
AU2016303485A1
(en)
|
2015-07-31 |
2018-03-01 |
Tarveda Therapeutics, Inc. |
Compositions and methods for immunomodulation
|
|
EP3350206A1
(en)
|
2015-09-14 |
2018-07-25 |
Alpine Immune Sciences, Inc. |
Tunable variant immunoglobulin superfamily domains and engineered cell therapy
|
|
EP3371210B1
(en)
*
|
2015-11-04 |
2022-05-25 |
Taipei Veterans General Hospital |
Combination therapy for malignant diseases
|
|
US20170145086A1
(en)
|
2015-11-25 |
2017-05-25 |
Visterra, Inc. |
Antibody molecules to april and uses thereof
|
|
CN108367069B
(zh)
|
2015-12-14 |
2022-08-23 |
宏观基因有限公司 |
对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
|
|
SG11201808457PA
(en)
|
2016-04-15 |
2018-10-30 |
Alpine Immune Sciences Inc |
Icos ligand variant immunomodulatory proteins and uses thereof
|
|
AU2017248830B2
(en)
|
2016-04-15 |
2023-03-09 |
Alpine Immune Sciences, Inc. |
CD80 variant immunomodulatory proteins and uses thereof
|
|
WO2017191274A2
(en)
|
2016-05-04 |
2017-11-09 |
Curevac Ag |
Rna encoding a therapeutic protein
|
|
IL262606B2
(en)
|
2016-05-18 |
2023-04-01 |
Albert Einstein College Medicine Inc |
pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them
|
|
CN109562126A
(zh)
|
2016-06-24 |
2019-04-02 |
美商生物细胞基因治疗有限公司 |
嵌合抗原受体(car)、组合物及其使用方法
|
|
WO2018022945A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd112 variant immunomodulatory proteins and uses thereof
|
|
EP3491013A1
(en)
|
2016-07-28 |
2019-06-05 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
MX2019004327A
(es)
|
2016-10-14 |
2019-10-14 |
Xencor Inc |
Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
|
|
EP3872180A1
(en)
|
2016-10-20 |
2021-09-01 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
FI3596116T3
(fi)
|
2017-03-16 |
2023-11-09 |
Alpine Immune Sciences Inc |
Immunomodulatorisia pd-l1-varianttiproteiineja ja niiden käyttöjä
|
|
JP2020511144A
(ja)
|
2017-03-16 |
2020-04-16 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用
|
|
MX2019010887A
(es)
|
2017-03-16 |
2019-10-15 |
Alpine Immune Sciences Inc |
Proteinas inmunomoduladoras de cb80 variante y usos de estas.
|
|
CA3064632A1
(en)
|
2017-06-20 |
2018-12-27 |
Dana-Farber Cancer Institute, Inc. |
Methods for modulating regulatory t cells, regulatory b cells, and immune responses using modulators of the april-taci interaction
|
|
CA3070468A1
(en)
|
2017-09-01 |
2019-03-07 |
Dana-Farber Cancer Institute, Inc. |
Immunogenic peptides specific to bcma and taci antigens for treatment of cancer
|
|
EP3694870A1
(en)
|
2017-10-10 |
2020-08-19 |
Alpine Immune Sciences, Inc. |
Ctla-4 variant immunomodulatory proteins and uses thereof
|
|
JP7282760B2
(ja)
|
2017-10-18 |
2023-05-29 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
|
|
GB201720426D0
(en)
|
2017-12-07 |
2018-01-24 |
Hummingbird Bioscience Pte Ltd |
CD47 and BCMA antigen-binding molecules
|
|
SG11202006148UA
(en)
|
2018-01-03 |
2020-07-29 |
Alpine Immune Sciences Inc |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
AU2019227979B2
(en)
|
2018-03-02 |
2024-09-05 |
Allogene Therapeutics, Inc. |
Inducible chimeric cytokine receptors
|
|
CN110522908A
(zh)
|
2018-05-25 |
2019-12-03 |
荣昌生物制药（烟台）有限公司 |
TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用
|
|
WO2019241758A1
(en)
|
2018-06-15 |
2019-12-19 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
|
WO2020028572A2
(en)
|
2018-08-01 |
2020-02-06 |
Unum Therapeutics Inc. |
ANTIBODY-COUPLED T CELL RECEPTORS (ACTRs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF
|
|
WO2020047329A1
(en)
|
2018-08-29 |
2020-03-05 |
Shattuck Labs, Inc. |
Chimeric proteins comprising extracellular domains and uses thereof
|
|
CN113544144A
(zh)
|
2018-09-19 |
2021-10-22 |
高山免疫科学股份有限公司 |
变体cd80融合蛋白和相关构建体的方法和用途
|
|
CN113573719A
(zh)
|
2018-11-08 |
2021-10-29 |
朱诺治疗学股份有限公司 |
治疗和t细胞调节的方法和组合
|
|
CN113727998A
(zh)
|
2018-11-30 |
2021-11-30 |
高山免疫科学股份有限公司 |
Cd86变体免疫调节蛋白及其用途
|
|
BR112021020447A2
(pt)
|
2019-04-17 |
2022-05-17 |
Alpine Immune Sciences Inc |
Métodos e usos de proteínas de fusão de ligante icos variante (icosl)
|
|
WO2020252421A2
(en)
|
2019-06-14 |
2020-12-17 |
Cugene, Inc. |
Novel interleukin-2 variants and bifunctional fusion molecules thereof
|
|
CN122060049A
(zh)
|
2019-09-13 |
2026-05-19 |
协和麒麟株式会社 |
DcR3变体
|
|
EP4074337B1
(en)
|
2019-12-10 |
2025-05-07 |
RemeGen Co., Ltd. |
Pharmaceutical taci-fc fusion protein formulation
|
|
JP2022539785A
(ja)
|
2019-12-24 |
2022-09-13 |
レメゲン シーオー．，エルティーディー． |
ＴＡＣＩ－Ｆｃ融合タンパク質及びその用途
|
|
US12202882B2
(en)
|
2020-05-08 |
2025-01-21 |
Alpine Immune Sciences, Inc. |
APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
|
|
AU2021324761A1
(en)
|
2020-08-12 |
2023-03-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
sBCMA variants and Fc fusion proteins thereof
|
|
AU2022269139A1
(en)
|
2021-05-07 |
2023-11-16 |
Alpine Immune Sciences, Inc. |
Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
|
|
KR20240030699A
(ko)
|
2022-08-31 |
2024-03-07 |
현대자동차주식회사 |
연료 전지 차량
|
|
IL319997A
(en)
|
2022-10-04 |
2025-06-01 |
Alpine Immune Sciences Inc |
Mutated taci-fc fusion proteins for use in the treatment of autoantibody-mediated diseases
|